# EDGAR Filing Document

**Accession Number:** 0001759425
**File Stem:** 0001231919-26-000093
**Filing Date:** 2026-1
**Character Count:** 76834
**Document Hash:** 2fdbadcc3ce587a3eb6005d5df05c638
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001231919-26-000093.hdr.sgml**: 20260127

**ACCESSION NUMBER**: 0001231919-26-000093

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 4

**FILED AS OF DATE**: 20260127

**DATE AS OF CHANGE**: 20260127

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Mirum Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001759425
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 831281555
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91075
- **FILM NUMBER:** 26565646

**BUSINESS ADDRESS:**
- **STREET 1:** 989 EAST HILLSDALE BOULEVARD, SUITE 300
- **CITY:** FOSTER CITY
- **STATE:** CA
- **ZIP:** 94404
- **BUSINESS PHONE:** 650-667-4085

**MAIL ADDRESS:**
- **STREET 1:** 989 EAST HILLSDALE BOULEVARD, SUITE 300
- **CITY:** FOSTER CITY
- **STATE:** CA
- **ZIP:** 94404
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Frazier Life Sciences IX, L.P.
- **CENTRAL INDEX KEY:** 0001720320

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 601 UNION STREET
- **STREET 2:** SUITE 3200
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98101
- **BUSINESS PHONE:** 206-254-7200

**MAIL ADDRESS:**
- **STREET 1:** 601 UNION STREET
- **STREET 2:** SUITE 3200
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98101

## Exhibit 10.1

**EXHIBIT 10.1**

**Transactions Relating to the Common Stock of the Issuer During the Past Sixty (60) Days**

The following table sets forth all transactions relating to the Common Stock of the Issuer that were effected during the past sixty (60) days by the applicable Reporting Person.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Reporting Person Name** | **Date of Event** | **Type of Transaction** | **Number of Shares** | **Price Per Share** | **Footnote** |
| FLS X | 1/23/2026 | Merger | 159277 | - | (1) |
| FLS XI | 1/23/2026 | Merger | 286698 | - | (1) |
| FLSPF | 1/23/2026 | Common Stock Warrant Purchase | 536412 | $68.4799 | (2) |
| FLS X | 1/23/2026 | Common Stock Purchase | 131425 | $68.48 | (2) |
| FLS XI | 1/23/2026 | Common Stock Purchase | 244232 | $68.48 | (2) |
| FLS XII | 1/23/2026 | Common Stock Purchase | 62931 | $68.48 | (2) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) On December 6, 2025, the Issuer entered into a merger agreement with Bluejay Therapeutics, Inc. (the "***BlueJay***"), which resulted in BlueJay becoming a wholly owned subsidiary of the Issuer (the "***BlueJay Merger***"). Both FLS X and FLS XI were stockholders of BlueJay and received these shares of the Issuer's Common Stock as a result of the BlueJay Merger.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) On December 7, 2025, FLSPF, FLS X, FLS XI and FLS XII entered into a Subscription Agreement with the Issuer, pursuant to which they agreed to purchase shares and/or pre-funded warrants to purchase shares of the Issuer's Common Stock immediately following the consummation of the BlueJay Merger.

## Exhibit 24.1

**EXHIBIT 24.1**

**POWER OF ATTORNEY**

**KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Gordon Empey and Jennifer Martin with full power to act singly, his true and lawful attorney-in-fact, with full power of substitution, to: (i) sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his capacity as a general partner of any partnership or limited liability company, pursuant to Section 13 or 16 of the Securities Exchange Act of 1934, as amended, and any and all regulations promulgated thereunder, (ii) file the same (including any amendments thereto), with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and any stock exchange or similar authority and (iii) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this power of attorney shall be in such form and shall contain such terms and conditions as such attorneyinfact may approve in such attorneyinfact's discretion, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate.**

**Each of the undersigned hereby grant to the attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted.**

**This power of attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to the attorney-in-fact.**

**IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 9th day of December, 2025.**

<u>/s/ Patrick J. Heron</u><br>

**Patrick J. Heron**

**<u>/s/</u> James N. Topper**<br>

**James N. Topper**

**<u>/s/</u> James Brush**<br>

**James Brush**

<u>/s/ Albert Cha</u><br>

**Albert Cha**

<u>/s/ Daniel Estes</u><br>

Daniel Estes

328364458 v1

## Exhibit 99.1

**EXHIBIT 99.1**

**JOINT FILING AGREEMENT**

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Shares of Common Stock of Mirum Pharmaceuticals, Inc.

Date: January 27, 2026

**FRAZIER LIFE SCIENCES IX, L.P.**

By: FHMLS IX, L.P., its General Partner

By: FHMLS IX, L.L.C., its General Partner

By: <u>/s/ Jennifer Martin</u>

Jennifer Martin, Chief Financial Officer

Date: January 27, 2026

**FHMLS IX, L.P.**

By: FHMLS IX, L.L.C., its General Partner

By: <u>/s/ Jennifer Martin</u>

Jennifer Martin, Chief Financial Officer

Date: January 27, 2026

**FHMLS IX, L.L.C.**

By: <u>/s/ Jennifer Martin</u>

Jennifer Martin, Chief Financial Officer

Date: January 27, 2026

**FRAZIER LIFE SCIENCES PUBLIC FUND, L.P.**

By: FHMLSP, L.P., its General Partner

By: FHMLSP, L.L.C., its General Partner

By: <u>/s/ Jennifer Martin</u>

Jennifer Martin, Chief Financial Officer

Date: January 27, 2026

**FHMLSP, L.P.**

By: FHMLSP, L.L.C., its General Partner

By: <u>/s/ Jennifer Martin</u>

Jennifer Martin, Chief Financial Officer

Date: January 27, 2026

**FHMLSP, L.L.C.**

By: <u>/s/ Jennifer Martin</u>

Jennifer Martin, Chief Financial Officer

------

Date: January 27, 2026

**FRAZIER LIFE SCIENCES X, L.P.**

By: FHMLS X, L.P., its General Partner

By: FHMLS X, L.L.C., its General Partner

By: <u>/s/ Jennifer Martin</u>

Jennifer Martin, Chief Financial Officer

Date: January 27, 2026

**FHMLS X, L.P.**

By: FHMLS X, L.L.C., its General Partner

By: <u>/s/ Jennifer Martin</u>

Jennifer Martin, Chief Financial Officer

Date: January 27, 2026

**FHMLS X, L.L.C.**

By: <u>/s/ Jennifer Martin</u>

Jennifer Martin, Chief Financial Officer

Date: January 27, 2026

**FRAZIER LIFE SCIENCES XI, L.P.**

By: FHMLS XI, L.P., its General Partner

By: FHMLS XI, L.L.C., its General Partner

By: <u>/s/ Jennifer Martin</u>

Jennifer Martin, Chief Financial Officer

Date: January 27, 2026

**FHMLS XI, L.P.**

By: FHMLS XI, L.L.C., its General Partner

By: <u>/s/ Jennifer Martin</u>

Jennifer Martin, Chief Financial Officer

Date: January 27, 2026

**FHMLS XI, L.L.C.**

By: <u>/s/ Jennifer Martin</u>

Jennifer Martin, Chief Financial Officer

Date: January 27, 2026

**FRAZIER LIFE SCIENCES XII, L.P.**

By: FHMLS XII, L.P., its General Partner

By: FHMLS XII, L.L.C., its General Partner

By: <u>/s/ Jennifer Martin</u>

Jennifer Martin, Chief Financial Officer

Date: January 27, 2026

**FHMLS XII, L.P.**

By: FHMLS XII, L.L.C., its General Partner

By: <u>/s/ Jennifer Martin</u>

Jennifer Martin, Chief Financial Officer

Date: January 27, 2026

**FHMLS XII, L.L.C.**

By: <u>/s/ Jennifer Martin</u>

Jennifer Martin, Chief Financial Officer

Date: January 27, 2026

By: <u>\*</u>

James N. Topper

Date: January 27, 2026

By: <u>\*</u>

Patrick J. Heron

Date: January 27, 2026

By: <u>/s/ Jennifer Martin</u>

Jennifer Martin, as Attorney-in-Fact

\* This Joint Filing Agreement was executed by Jennifer Martin on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on January 27, 2026.

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 8)**

**MIRUM PHARMACEUTICALS, INC.**

*(Name of Issuer)*

**Common Stock, par value $0.0001 per share**

*(Title of Class of Securities)*

**604749101**

*(CUSIP Number)*

**Jennifer Martin**<br>1700 Seventh Ave, Suite 1120<br>Seattle WA 98101<br>(206) 451-8040

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**01/23/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **604749101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Frazier Life Sciences IX, L.P.** | Name of reporting person<br>**Frazier Life Sciences IX, L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**3566912.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**3566912.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**3566912.00** | Aggregate amount beneficially owned by each reporting person<br>**3566912.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**5.9%** | Percent of class represented by amount in Row (11)<br>**5.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** The percentage listed in row 13 is calculated based on the sum of (i) 51,393,574 shares of Common Stock outstanding on October 31, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 4, 2025, (ii) 5,196,009 shares of Common Stock that were anticipated to be issued in connection with the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, (iii) 2,385,149 shares of Common Stock that were anticipated to be issued by the Issuer in a private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, and (iv) 1,000,000 shares of Common Stock that were anticipated to be issued by the Issuer in an additional private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 19, 2025.

| **CUSIP No.** | **604749101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**FHMLS IX, L.P.** | Name of reporting person<br>**FHMLS IX, L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**3566912.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**3566912.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**3566912.00** | Aggregate amount beneficially owned by each reporting person<br>**3566912.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**5.9%** | Percent of class represented by amount in Row (11)<br>**5.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** The percentage listed in row 13 is calculated based on the sum of (i) 51,393,574 shares of Common Stock outstanding on October 31, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 4, 2025, (ii) 5,196,009 shares of Common Stock that were anticipated to be issued in connection with the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, (iii) 2,385,149 shares of Common Stock that were anticipated to be issued by the Issuer in a private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, and (iv) 1,000,000 shares of Common Stock that were anticipated to be issued by the Issuer in an additional private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 19, 2025.

| **CUSIP No.** | **604749101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**FHMLS IX, L.L.C.** | Name of reporting person<br>**FHMLS IX, L.L.C.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**3566912.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**3566912.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**3566912.00** | Aggregate amount beneficially owned by each reporting person<br>**3566912.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**5.9%** | Percent of class represented by amount in Row (11)<br>**5.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** The percentage listed in row 13 is calculated based on the sum of (i) 51,393,574 shares of Common Stock outstanding on October 31, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 4, 2025, (ii) 5,196,009 shares of Common Stock that were anticipated to be issued in connection with the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, (iii) 2,385,149 shares of Common Stock that were anticipated to be issued by the Issuer in a private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, and (iv) 1,000,000 shares of Common Stock that were anticipated to be issued by the Issuer in an additional private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 19, 2025.

| **CUSIP No.** | **604749101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Frazier Life Sciences X, L.P.** | Name of reporting person<br>**Frazier Life Sciences X, L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**459010.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**459010.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**459010.00** | Aggregate amount beneficially owned by each reporting person<br>**459010.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.8%** | Percent of class represented by amount in Row (11)<br>**0.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** The percentage listed in row 13 is calculated based on the sum of (i) 51,393,574 shares of Common Stock outstanding on October 31, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 4, 2025, (ii) 5,196,009 shares of Common Stock that were anticipated to be issued in connection with the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, (iii) 2,385,149 shares of Common Stock that were anticipated to be issued by the Issuer in a private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, and (iv) 1,000,000 shares of Common Stock that were anticipated to be issued by the Issuer in an additional private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 19, 2025.

| **CUSIP No.** | **604749101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**FHMLS X, L.P.** | Name of reporting person<br>**FHMLS X, L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**459010.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**459010.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**459010.00** | Aggregate amount beneficially owned by each reporting person<br>**459010.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.8%** | Percent of class represented by amount in Row (11)<br>**0.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** The percentage listed in row 13 is calculated based on the sum of (i) 51,393,574 shares of Common Stock outstanding on October 31, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 4, 2025, (ii) 5,196,009 shares of Common Stock that were anticipated to be issued in connection with the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, (iii) 2,385,149 shares of Common Stock that were anticipated to be issued by the Issuer in a private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, and (iv) 1,000,000 shares of Common Stock that were anticipated to be issued by the Issuer in an additional private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 19, 2025.

| **CUSIP No.** | **604749101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**FHMLS X, L.L.C.** | Name of reporting person<br>**FHMLS X, L.L.C.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**459010.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**459010.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**459010.00** | Aggregate amount beneficially owned by each reporting person<br>**459010.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.8%** | Percent of class represented by amount in Row (11)<br>**0.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** The percentage listed in row 13 is calculated based on the sum of (i) 51,393,574 shares of Common Stock outstanding on October 31, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 4, 2025, (ii) 5,196,009 shares of Common Stock that were anticipated to be issued in connection with the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, (iii) 2,385,149 shares of Common Stock that were anticipated to be issued by the Issuer in a private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, and (iv) 1,000,000 shares of Common Stock that were anticipated to be issued by the Issuer in an additional private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 19, 2025.

| **CUSIP No.** | **604749101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Frazier Life Sciences Public Fund, L.P.** | Name of reporting person<br>**Frazier Life Sciences Public Fund, L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**2514947.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**2514947.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2514947.00** | Aggregate amount beneficially owned by each reporting person<br>**2514947.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.2%** | Percent of class represented by amount in Row (11)<br>**4.2%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** The amounts reported in rows 8, 10 and 11 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See Item 5(a) to this Statement.

The percentage listed in row 13 is calculated based on the sum of (i) 51,393,574 shares of Common Stock outstanding on October 31, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 4, 2025, (ii) 5,196,009 shares of Common Stock that were anticipated to be issued in connection with the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, (iii) 2,385,149 shares of Common Stock that were anticipated to be issued by the Issuer in a private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, and (iv) 1,000,000 shares of Common Stock that were anticipated to be issued by the Issuer in an additional private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 19, 2025.

| **CUSIP No.** | **604749101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**FHMLSP, L.P.** | Name of reporting person<br>**FHMLSP, L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**2514947.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**2514947.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2514947.00** | Aggregate amount beneficially owned by each reporting person<br>**2514947.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.2%** | Percent of class represented by amount in Row (11)<br>**4.2%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** The amounts reported in rows 8, 10 and 11 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See Item 5(a) to this Statement.

The percentage listed in row 13 is calculated based on the sum of (i) 51,393,574 shares of Common Stock outstanding on October 31, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 4, 2025, (ii) 5,196,009 shares of Common Stock that were anticipated to be issued in connection with the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, (iii) 2,385,149 shares of Common Stock that were anticipated to be issued by the Issuer in a private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, and (iv) 1,000,000 shares of Common Stock that were anticipated to be issued by the Issuer in an additional private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 19, 2025.

| **CUSIP No.** | **604749101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**FHMLSP, L.L.C.** | Name of reporting person<br>**FHMLSP, L.L.C.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**2514947.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**2514947.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2514947.00** | Aggregate amount beneficially owned by each reporting person<br>**2514947.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.2%** | Percent of class represented by amount in Row (11)<br>**4.2%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** The amounts reported in rows 8, 10 and 11 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See Item 5(a) to this Statement.

The percentage listed in row 13 is calculated based on the sum of (i) 51,393,574 shares of Common Stock outstanding on October 31, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 4, 2025, (ii) 5,196,009 shares of Common Stock that were anticipated to be issued in connection with the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, (iii) 2,385,149 shares of Common Stock that were anticipated to be issued by the Issuer in a private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, and (iv) 1,000,000 shares of Common Stock that were anticipated to be issued by the Issuer in an additional private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 19, 2025.

| **CUSIP No.** | **604749101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Frazier Life Sciences XI, L.P.** | Name of reporting person<br>**Frazier Life Sciences XI, L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1075884.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1075884.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1075884.00** | Aggregate amount beneficially owned by each reporting person<br>**1075884.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**1.8%** | Percent of class represented by amount in Row (11)<br>**1.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** The percentage listed in row 13 is calculated based on the sum of (i) 51,393,574 shares of Common Stock outstanding on October 31, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 4, 2025, (ii) 5,196,009 shares of Common Stock that were anticipated to be issued in connection with the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, (iii) 2,385,149 shares of Common Stock that were anticipated to be issued by the Issuer in a private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, and (iv) 1,000,000 shares of Common Stock that were anticipated to be issued by the Issuer in an additional private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 19, 2025.

| **CUSIP No.** | **604749101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**FHMLS XI, L.P.** | Name of reporting person<br>**FHMLS XI, L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1075884.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1075884.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1075884.00** | Aggregate amount beneficially owned by each reporting person<br>**1075884.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**1.8%** | Percent of class represented by amount in Row (11)<br>**1.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** The percentage listed in row 13 is calculated based on the sum of (i) 51,393,574 shares of Common Stock outstanding on October 31, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 4, 2025, (ii) 5,196,009 shares of Common Stock that were anticipated to be issued in connection with the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, (iii) 2,385,149 shares of Common Stock that were anticipated to be issued by the Issuer in a private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, and (iv) 1,000,000 shares of Common Stock that were anticipated to be issued by the Issuer in an additional private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 19, 2025.

| **CUSIP No.** | **604749101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**FHMLS XI, L.L.C.** | Name of reporting person<br>**FHMLS XI, L.L.C.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1075884.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1075884.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1075884.00** | Aggregate amount beneficially owned by each reporting person<br>**1075884.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**1.8%** | Percent of class represented by amount in Row (11)<br>**1.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** The percentage listed in row 13 is calculated based on the sum of (i) 51,393,574 shares of Common Stock outstanding on October 31, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 4, 2025, (ii) 5,196,009 shares of Common Stock that were anticipated to be issued in connection with the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, (iii) 2,385,149 shares of Common Stock that were anticipated to be issued by the Issuer in a private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, and (iv) 1,000,000 shares of Common Stock that were anticipated to be issued by the Issuer in an additional private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 19, 2025.

| **CUSIP No.** | **604749101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Frazier Life Sciences XII, L.P.** | Name of reporting person<br>**Frazier Life Sciences XII, L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**62931.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**62931.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**62931.00** | Aggregate amount beneficially owned by each reporting person<br>**62931.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.1%** | Percent of class represented by amount in Row (11)<br>**0.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** The percentage listed in row 13 is calculated based on the sum of (i) 51,393,574 shares of Common Stock outstanding on October 31, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 4, 2025, (ii) 5,196,009 shares of Common Stock that were anticipated to be issued in connection with the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, (iii) 2,385,149 shares of Common Stock that were anticipated to be issued by the Issuer in a private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, and (iv) 1,000,000 shares of Common Stock that were anticipated to be issued by the Issuer in an additional private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 19, 2025.

| **CUSIP No.** | **604749101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**FHMLS XII, L.P.** | Name of reporting person<br>**FHMLS XII, L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**62931.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**62931.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**62931.00** | Aggregate amount beneficially owned by each reporting person<br>**62931.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.1%** | Percent of class represented by amount in Row (11)<br>**0.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** The percentage listed in row 13 is calculated based on the sum of (i) 51,393,574 shares of Common Stock outstanding on October 31, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 4, 2025, (ii) 5,196,009 shares of Common Stock that were anticipated to be issued in connection with the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, (iii) 2,385,149 shares of Common Stock that were anticipated to be issued by the Issuer in a private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, and (iv) 1,000,000 shares of Common Stock that were anticipated to be issued by the Issuer in an additional private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 19, 2025.

| **CUSIP No.** | **604749101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**FHMLS XII, L.L.C.** | Name of reporting person<br>**FHMLS XII, L.L.C.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**62931.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**62931.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**62931.00** | Aggregate amount beneficially owned by each reporting person<br>**62931.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.1%** | Percent of class represented by amount in Row (11)<br>**0.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** The percentage listed in row 13 is calculated based on the sum of (i) 51,393,574 shares of Common Stock outstanding on October 31, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 4, 2025, (ii) 5,196,009 shares of Common Stock that were anticipated to be issued in connection with the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, (iii) 2,385,149 shares of Common Stock that were anticipated to be issued by the Issuer in a private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, and (iv) 1,000,000 shares of Common Stock that were anticipated to be issued by the Issuer in an additional private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 19, 2025.

| **CUSIP No.** | **604749101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**James N. Topper** | Name of reporting person<br>**James N. Topper** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**4025922.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**4025922.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**4025922.00** | Aggregate amount beneficially owned by each reporting person<br>**4025922.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**6.7%** | Percent of class represented by amount in Row (11)<br>**6.7%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** The shares listed in rows 8, 10 and 11 represents (i) 3,566,912 shares of Common Stock held directly by Frazier Life Sciences IX, L.P., and (ii) 459,010 shares of Common Stock held directly by Frazier Life Sciences X, L.P.

The percentage listed in row 13 is calculated based on the sum of (i) 51,393,574 shares of Common Stock outstanding on October 31, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 4, 2025, (ii) 5,196,009 shares of Common Stock that were anticipated to be issued in connection with the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, (iii) 2,385,149 shares of Common Stock that were anticipated to be issued by the Issuer in a private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, and (iv) 1,000,000 shares of Common Stock that were anticipated to be issued by the Issuer in an additional private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 19, 2025.

| **CUSIP No.** | **604749101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Patrick J. Heron** | Name of reporting person<br>**Patrick J. Heron** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**82482.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**4025922.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**82482.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**4025922.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**4108404.00** | Aggregate amount beneficially owned by each reporting person<br>**4108404.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**6.8%** | Percent of class represented by amount in Row (11)<br>**6.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** The shares listed in rows 8, 10 and 11 represents (i) 5,703 shares of Common Stock held directly by the Reporting Person, (ii) 76,779 shares of Common Stock that are issuable upon the exercise of options held directly by the Reporting Person, (iii) 3,566,912 shares of Common Stock held directly by Frazier Life Sciences IX, L.P., and (iv) 459,010 shares of Common Stock held directly by Frazier Life Sciences X, L.P.

The percentage listed in row 13 is calculated based on the sum of (i) 51,393,574 shares of Common Stock outstanding on October 31, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 4, 2025, (ii) 5,196,009 shares of Common Stock that were anticipated to be issued in connection with the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, (iii) 2,385,149 shares of Common Stock that were anticipated to be issued by the Issuer in a private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, (iv) 1,000,000 shares of Common Stock that were anticipated to be issued by the Issuer in an additional private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 19, 2025, and (v) 76,779 shares of Common Stock that are issuable upon the exercise of options held directly by the Reporting Person.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.0001 per share

**(b) Name of Issuer:**
MIRUM PHARMACEUTICALS, INC.

**(c) Address of Issuer's Principal Executive Offices:**
989 E Hillsdale Blvd., Suite 300, FOSTER CITY, CA, 94404

This Amendment No. 8 ("Amendment No. 8") to Schedule 13D amends the statement on Schedule 13D filed on July 26 2019 (the "Original Schedule 13D") as amended on April 29, 2020, December 18, 2020, August 16, 2022, April 14, 2023, September 5, 2023, August 20, 2025 and November 4, 2025 (the "Prior Amendments", and together with the Original Schedule 13D and this Amendment No. 8, the "Schedule 13D"). Except as otherwise specified in this Amendment No. 8, all items in the Original Schedule 13D, as amended by the Prior Amendments, are unchanged. All capitalized terms used in this Amendment No. 8 and not otherwise defined herein have the meanings ascribed to such terms in the Original Schedule 13D, as amended by the Prior Amendments.

**Item 4. Purpose of Transaction**

Item 4 is hereby amended and restated in its entirety to read as follows:

Each of FLS IX, FLS X, FLSPF, FLS XI and FLS XII acquired the FLS IX Shares, the FLS X Shares, the FLSPF Shares, the FLS XI Shares and the FLS XII Shares, as the case may be, for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, FLS IX, FLS X, FLSPF, FLS XI and FLS XII and the other Reporting Persons may dispose of or acquire additional shares of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in:

 	(a)	The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer;

 	(b)	An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries;

 	(c)	A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries;

 	(d)	Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;

 	(e)	Any material change in the present capitalization or dividend policy of the Issuer;

 	(f)	Any other material change in the Issuer's business or corporate structure;

 	(g)	Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person;

 	(h)	Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;

 	(i)	A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934, as amended; or

 	(j)	Any action similar to any of those enumerated above.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The information contained in Rows 7, 8, 9, 10, 11, and 13 of each Reporting Person's cover page to this Schedule 13D (including the footnotes thereto) is incorporated by reference into this Item 5.

FLSPF directly holds 2,514,947 shares of Common Stock of the Issuer (the "FLSPF Shares"). FHMLSP, L.P. is the general partner of FLSPF and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPF.

FLS IX directly holds 3,566,912 shares of Common Stock of the Issuer (the "FLS IX Shares"). FHMLS IX, L.P. is the general partner of FLS IX and FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. Heron and Topper are the members of FHMLS IX, L.L.C. and therefore share voting and investment power over the FLS IX Shares.

FLS X directly holds 459,010 shares of Common Stock of the Issuer (the "FLS X Shares"). FHMLS X, L.P. is the general partner of FLS X and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Heron and Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the FLS X Shares.

FLS XI directly holds 1,075,884 shares of Common Stock of the Issuer (the "FLS XI Shares"). FHMLS XI, L.P. is the general partner of FLS XI and the general partner of FHMLS XI, L.P. is FHMLS XI, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XI.

FLS XII directly holds 62,931 shares of Common Stock of the Issuer (the "FLS XI Shares"). FHMLS XII, L.P. is the general partner of FLS XII and the general partner of FHMLS XII, L.P. is FHMLS XII, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XII.

The above referenced beneficial ownership and amounts reflected on the cover pages hereto do not include certain prefunded warrants to acquire shares of Common Stock (the "Warrants"), the exercise of which is subject to certain beneficial ownership limitations. In this regard, FLSPF holds Warrants to purchase 536,412 shares of Common Stock, each of which cannot be exercised, if, upon giving effect to such exercise, the aggregate number of shares of Common Stock beneficially owned by the holder of such Warrant (together with its affiliates or any other persons acting as a group together with such holder) would exceed 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.

Except as specifically stated herein, the filing of this Schedule 13D shall not be construed as an admission that any Reporting Person or any of the foregoing is, for the purposes of Section 13(d) and/or Section 13(g) of the Act or otherwise, the beneficial owner of any securities covered by this Schedule 13D or a member of a "group" with any other person.

**(b)**
—

**(c)**
Except as set forth on Exhibit 10.1 of this Schedule 13D, none of the Reporting Persons has effected any transactions relating to the Ordinary Shares during the past 60 days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Registration Rights Agreement

Pursuant to the terms of a Registration Rights Agreement with the Issuer dated December 7, 2025 (the "Registration Rights Agreement"), certain holders of the Issuer's Common Stock, including FLSPF, FLS X, FLS XI, FLS XII, are entitled to rights with respect to the registration under the Securities Act of 1933, as amended, of the shares of Common Stock or the shares of Common Stock issuable upon exercise of the pre-funded warrants that were purchased on January 23, 2026 (the "Registrable Securities").  Under the terms of the Registration Rights Agreement, the Issuer has agreed to prepare and file a registration statement with the SEC to register for resale the Registrable Securities. The Company has agreed to be responsible for all fees and expenses incurred in connection with the registration of the Registrable Securities.

Other than as described in this Schedule 13D, to the best of the Reporting Persons' knowledge, there are no other contracts, arrangements, understandings or relationships (legal or otherwise) among the persons named in Item 2 and between such persons and any person with respect to any securities of the Issuer.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Frazier Life Sciences IX, L.P.

**Signature:** /s/ Jennifer Martin

**Name/Title:** By Jennifer Martin, CFO of FHMLS IX, L.L.C., GP of FHMLS IX, L.P., GP of Frazier Life Sciences IX, L.P.

**Date:** 01/27/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** FHMLS IX, L.P.

**Signature:** /s/ Jennifer Martin

**Name/Title:** By Jennifer Martin, CFO of FHMLS IX, L.L.C., GP of FHMLS IX, L.P.

**Date:** 01/27/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** FHMLS IX, L.L.C.

**Signature:** /s/ Jennifer Martin

**Name/Title:** By Jennifer Martin, CFO of FHMLS IX, L.L.C.

**Date:** 01/27/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Frazier Life Sciences X, L.P.

**Signature:** /s/ Jennifer Martin

**Name/Title:** By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P.

**Date:** 01/27/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** FHMLS X, L.P.

**Signature:** /s/ Jennifer Martin

**Name/Title:** By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P.

**Date:** 01/27/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** FHMLS X, L.L.C.

**Signature:** /s/ Jennifer Martin

**Name/Title:** By Jennifer Martin, CFO of FHMLS X, L.L.C.

**Date:** 01/27/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Frazier Life Sciences Public Fund, L.P.

**Signature:** /s/ Jennifer Martin

**Name/Title:** By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.

**Date:** 01/27/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** FHMLSP, L.P.

**Signature:** /s/ Jennifer Martin

**Name/Title:** By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.

**Date:** 01/27/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** FHMLSP, L.L.C.

**Signature:** /s/ Jennifer Martin

**Name/Title:** By Jennifer Martin, CFO of FHMLSP, L.L.C.

**Date:** 01/27/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Frazier Life Sciences XI, L.P.

**Signature:** /s/ Jennifer Martin

**Name/Title:** By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.

**Date:** 01/27/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** FHMLS XI, L.P.

**Signature:** /s/ Jennifer Martin

**Name/Title:** By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.

**Date:** 01/27/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** FHMLS XI, L.L.C.

**Signature:** /s/ Jennifer Martin

**Name/Title:** By Jennifer Martin, CFO of FHMLS XI, L.L.C.

**Date:** 01/27/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Frazier Life Sciences XII, L.P.

**Signature:** /s/ Jennifer Martin

**Name/Title:** By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P., GP of Frazier Life Sciences XII, L.P.

**Date:** 01/27/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** FHMLS XII, L.P.

**Signature:** /s/ Jennifer Martin

**Name/Title:** By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P.

**Date:** 01/27/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** FHMLS XII, L.L.C.

**Signature:** /s/ Jennifer Martin

**Name/Title:** By Jennifer Martin, CFO of FHMLS XII, L.L.C.

**Date:** 01/27/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** James N. Topper

**Signature:** /s/ Jennifer Martin

**Name/Title:** By Jennifer Martin, Attorney-in-Fact for Patrick J. Heron, pursuant to Power of Attorney

**Date:** 01/27/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Patrick J. Heron

**Signature:** /s/ Jennifer Martin

**Name/Title:** By Jennifer Martin, Attorney-in-Fact for Patrick J. Heron, pursuant to Power of Attorney

**Date:** 01/27/2026